Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04413357 · ClinicalTrials.gov registry record · NA
Glycemic Response in Persons with Type 2 Diabetes
A NA study, sponsored by Société des Produits Nestlé (SPN).
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT04413357: Completed NA study, sponsored by Société des Produits Nestlé (SPN).
NCT04413357 is a NA study that has completed, run by Société des Produits Nestlé (SPN). The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04413357, a NA study, has completed, sponsored by Société des Produits Nestlé (SPN).
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
This will be a randomized crossover design with nutrition supplement interventions.
Primary Outcome
Area under the blood glucose curve (AUC 0-240 minutes)
Interventions
- OTHER Balanced Nutritional Drink
- OTHER Diabetes Specific, Balanced Nutritional Drink (DMA)
- OTHER Diabetes Specific, Balanced Nutritional Drink DMB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-05-18 |
| Est. Completion | 2020-08-11 |
| Phase | NA |
What the finished NCT04413357 record still lists
NCT04413357 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Balanced Nutritional Drink is the first listed.
NCT04413357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04413357 about?
NCT04413357 is a clinical study titled "Glycemic Response in Persons with Type 2 Diabetes". This will be a randomized crossover design with nutrition supplement interventions.
What is the current status of trial NCT04413357?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2020-05-18. Estimated completion is 2020-08-11.
What interventions are being tested in trial NCT04413357?
The interventions under investigation include: Balanced Nutritional Drink (OTHER), Diabetes Specific, Balanced Nutritional Drink (DMA) (OTHER), Diabetes Specific, Balanced Nutritional Drink DMB (OTHER).
Who is sponsoring clinical trial NCT04413357?
This trial is sponsored by Société des Produits Nestlé (SPN), which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04413357's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy